The following is a history of financings and IRR* calculations for a select group of companies that Creation Capital clients had the the opportunity to invest in. |
|||||
* Internal Rate of Return |
|||||
| Company | Date | Round | Price per Share | ||
| Myriad Genetics | |||||
 |
February 1993 | Series A | $5.60 |
||
| February 1995 | Series B | $14.00 |
|||
| Result: | October 1995 | IPO Cowen-UBS |
$18.00 |
||
| Stock Price High | June 2000 | *$272.00 |
|||
| IRR to peak 44% | |||||
|
*Not adjusted for 2:1 split 09/00
|
|||||
| Acacia Biosciences / Rosetta Inpharmatics | |||||
 |
November 1995 | Seed | $2.50 |
||
| February 1996 | Seed II | $2.90 |
|||
| November 1996 | Series A | $4.00 |
|||
| February 1999 | Merger | ||||
| Result: | August 2000 | IPO Lehman Bros. |
$14.00 |
||
| Stock Price High | September 2000 | $38.25 |
|||
| IRR to peak 36% | |||||
Acquired by Merck as a wholly owned subsidiary in May 2001 for $620 million |
|||||
| Amedica Corporation | |||||
 |
January 2004 | Series A | $0.60 |
||
| October 2004 | Series B | $1.20 |
|||
| February 2006 | Series C | $2.00 |
|||
| April 2007 | Series D | $3.00 |
|||
| Result: | IPO filed
5/22/07 Morgan Stanley Jeffries CIBC |
||||
| Back to Top | |||||
